Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy
Radiographic Contrast Agent Nephropathy
About this trial
This is an interventional prevention trial for Radiographic Contrast Agent Nephropathy focused on measuring Contrast induced nephropathy, Diabetes Mellitus, Dexmedetomidine
Eligibility Criteria
Inclusion Criteria:
- Scheduled for percutaneous coronary angiography
- > 18 yo
- Diabetic patients
- Creatinin value < 3 mg/dl
Exclusion Criteria:
- Contrast agent hypersensitivity
- Pregnant patients
- Creatinin value ≥3mg/dl
- patients have acute renal failure
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
Control
Dexmedetomidine
Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours. During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered. 100 ml/10min 0.9 % NaCl administered intravenously just before the angiography. 1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography.
Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours. During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered. Dexmedetomidine was diluted as 1 μg/ml. 1 μg/kg/10min dexmedetomidine administered intravenously just before the angiography. 1 μg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography.